Immuneering Corporation (IMRX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Cambridge, MA, United States. The current CEO is Benjamin J. Zeskind.
IMRX has IPO date of 2021-07-30, 54 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $196.4M.
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
